title: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
abstract: OBJECTIVE
  To estimate the efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
  
  
  METHODS
  We followed the course of 745 women with a first breast cancer and a family history of breast and/or ovarian cancer who underwent contralateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. Family history information and cancer follow-up information were obtained from the medical record, a study-specific questionnaire, and telephone follow-up. Life-tables for contralateral breast cancers, which consider age at first breast cancer, current age, and type of family history, were used to calculate the number of breast cancers expected in our cohort had they not had a prophylactic mastectomy.
  
  
  RESULTS
  Of the 745 women in our cohort, 388 were premenopausal (age < 50 years) and 357 were post- menopausal. Eight women developed a contralateral breast cancer. Six events were observed among the premenopausal women, compared with 106.2 predicted, resulting in a risk reduction of 94.4% (95% confidence interval [CI], 87.7% to 97.9%). For the 357 postmenopausal women, 50.3 contralateral breast cancers were predicted, whereas only two were observed, representing a 96.0% risk reduction (95% CI, 85.6% to 99.5%).
  
  
  CONCLUSIONS
  The incidence of contralateral breast cancer seems to be reduced significantly after contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
authors.affiliation: Division of Medical Oncology, Mayo Clinic Cancer Center, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: McDonnell
authors.forename: D J
authors.initials: DJ
authors.lastname: Schaid
authors.forename: J L
authors.initials: JL
authors.lastname: Myers
authors.forename: C S
authors.initials: CS
authors.lastname: Grant
authors.forename: J H
authors.initials: JH
authors.lastname: Donohue
authors.forename: J E
authors.initials: JE
authors.lastname: Woods
authors.forename: M H
authors.initials: MH
authors.lastname: Frost
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: D L
authors.initials: DL
authors.lastname: Sitta
authors.forename: J M
authors.initials: JM
authors.lastname: Slezak
authors.forename: T B
authors.initials: TB
authors.lastname: Crotty
authors.forename: R B
authors.initials: RB
authors.lastname: Jenkins
authors.forename: T A
authors.initials: TA
authors.lastname: Sellers
authors.forename: L C
authors.initials: LC
authors.lastname: Hartmann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000235:genetics